Please use this identifier to cite or link to this item:
|Title:||Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions|
|Authors:||Moraes, Maria Carolina S.|
Andrade, Annabel Quinet de
Carvalho, Helotonio [UNIFESP]
Agnoletto, Mateus H.
Henriques, Joao A. P.
Menck, Carlos F. M.
Universidade de São Paulo (USP)
Univ Paris Sud
Universidade Federal de São Paulo (UNIFESP)
Univ Fed Rio Grande do Sul
Fed Univ Hlth Sci Porto Alegre UFCSPA
DNA polymerase eta (pol eta)
|Citation:||Cancer Letters. Clare: Elsevier B.V., v. 314, n. 1, p. 108-118, 2012.|
|Abstract:||Doxorubicin (DOX) is an important tumor chemotherapeutic agent, acting mainly by genotoxic action. This work focus on cell processes that help cell survival, after DOX-induced DNA damage. in fact, cells deficient for XPA or DNA polymerase eta (pol eta, XPV) proteins (involved in distinct DNA repair pathways) are highly DOX-sensitive. Moreover, LY294002, an inhibitor of PIKK kinases, showed a synergistic killing effect in cells deficient in these proteins, with a strong induction of G2/M cell cycle arrest. Taken together, these results indicate that XPA and pol eta proteins participate in cell resistance to DOX-treatment, and kinase inhibitors can selectively enhance its killing effects, probably reducing the cell ability to recover from breaks induced in DNA. (C) 2011 Elsevier Ireland Ltd. All rights reserved.|
|Appears in Collections:||Artigo|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.